Etofibrate is a combination of niacin and clofibrate that acts as a hypolipidemic agent. In vivo, etofibrate decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content in rats. It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation in a carotid artery balloon injury rat model. Formulations containing etofibrate have been used to treat hyperlipidemia.
